Table 1.
Demographics and clinical characteristics of the antipsychotic-related DRESS syndrome cases
| Characteristics of the DRESS syndrome case | Total sample (n = 1534) |
|---|---|
| Age (years), median (Q1–Q3) | 41.0 (29.0–54.0) |
| Sex (females), n (%) | 642 (41.9) |
| BMI (kg/m2), median (Q1–Q3) | 23.9 (21.3–28.4) |
| Dose (PDD/DDD), median (Q1–Q3) | 0.7 (0.2–1.3) |
| AP treatment duration (days), median (Q1–Q3) | 22.0 (12.0–52.0) |
| DRESS symptoms duration (days), median (Q1–Q3) | 11.0 (5.0–25.0) |
| Lethal, n (%) | 164 (10.7) |
| More than one AP, n (%) | 670 (43.7) |
| Administration route, n (%) | |
| Oral | 998 (65.1) |
| Unknown | 177 (11.5) |
| Intramuscular | 29 (1.9) |
| Intravenous | 12 (0.8) |
| Other | 17 (1.1) |
| Reported co-medication with DRESS-related potential, n (%) | |
| Anticonvulsants | 547 (35.7) |
| Antibiotics | 91 (5.9) |
| Miscellaneous | 53 (3.5) |
| Country, n (%) | |
| United States | 391 (25.5) |
| United Kingdom | 214 (14.0) |
| Germany | 148 (9.6) |
| France | 143 (9.3) |
| Australia | 138 (9.0) |
| Japan | 92 (6.0) |
| Canada | 91 (5.9) |
| Other (40 countries) | 261 (17) |
| Reporter, n (%) | |
| Physician | 698 (45.5) |
| Other health professional | 170 (11.1) |
| Pharmacist | 132 (8.6) |
| Consumer/non-health professional | 39 (2.5) |
| Lawyer | 6 (0.4) |
AP antipsychotic, BMI body mass index, DDD defined daily dose, DRESS drug reaction with eosinophilia and systemic symptoms, PDD prescribed daily dose, Q1 first quartile, Q3 third quartile